

# Innovative Discovery Center



**PRESTIGE BIOPHARMA**  
Innovative Discovery Center

# Innovation for Life

## We invite you to our open innovation ecosystem.

IDC (Innovative Discovery Center) aims to foster growth towards an 'Open Innovation Center'. Through exchange, collaboration, and convergence of science and technology, IDC strives to advance a future that contributes to human life. Our value grows through community efforts.

We will achieve scientific accomplishments through mutual contributions.



## We connect your great inspirations together.

We are driven by the aspiration to serve as catalysts in uniting the extraordinary inspirations that span across the globe. By nurturing a network of open connections among diverse scientific endeavors, our aim is to unveil the hidden treasures of potential, causing them to rise and shimmer upon the tranquil surface of water, evoking a sense of awe and wonder.

IDC is located in Busan, a beautiful coastal Metropolitan city in South Korea.

## Let's connect our futures together.

IDC is fostering its own potential by leveraging the "fast drop & go" strategy in developing its pipeline of biosimilars and first-in-class therapeutics. We are actively pursuing collaborations with diverse universities and research institutions to establish an open ecosystem.

We seek to connect and harmonize scientific experiences and inspirations, while fostering an environment of open innovation where the value of new modalities can grow and evolve together. Discover the balance between life and work in Busan. Busan has been chosen as one of the world's best traveling city by National Geographic in 2023.

# Innovative Drug Pipeline



	Ulenistamab (PBP1510)	Pancreatic cancer, Ovarian cancer	Clinical (Phase 1/2a)	
First-in-class	PBP1710	Solid tumor	Preclinical	
	IDC111	Solid tumor	Basic Research	
Bispecific Antibody	IDC001	Solid tumor	Basic Research	
	IDC002	Solid tumor	Basic Research	
	IDC003	Solid tumor	Basic Research	
	IDC005	Solid tumor	Discovery	
	IDC007	Critical immune disorders	Discovery	
	IDC008	Solid tumor	Discovery	
	IDC009	Solid tumor	Discovery	
	IDC010	Immune disease	Discovery	
	Novel Concept Antibody	IDC331	Solid tumor	Discovery
		IDC332	Solid tumor	Discovery
IDC333		Solid tumor	Discovery	
IDC334		Solid tumor	Discovery	
Antibody Drug Conjugate	IDC441	Solid tumor	Basic Research	

## First-in-Class Antibody PBP1510 (Ulenistamab)



- Development stage : Phase 1/2a (EU, USA & Asia)
- Indication : Pancreatic cancer, Ovarian cancer
- Orphan Drug Designation by FDA, EMA, MFDS
- Fast Track Designation by FDA

## First-in-Class Antibody PBP1710 (Anti-CTHRC1)

- Development stage : Preclinical
- Indication : Solid tumors
- Patent registered in Korea in January 2023

## First-in-Class PAUF-detecting Diagnostic Kit A Powerful Tool for Screening and Detection of pancreatic Cancer

**Diagnosis** PAUF detection in blood as pancreatic cancer screening

- Carbohydrate antigen 19-9(CA19-9) is the only approved biomarker for Pancreatic cancer so far, but it has low specificity.
- The novel diagnostic method exhibits high sensitivity and specificity in detecting PAUF.
- In our preliminary data, PAUF showed a superior diagnostic power that can overcome the weaknesses of current biomarker in pancreatic cancer.



The World's First Biomarker-based Diagnostic Test for Pancreatic Cancer Early Detection  
Inviting Clinical Laboratories for LDT partnership



## Innovative Discovery Center (IDC)

Prestige Biopharma IDC Co., Ltd.  
2776-8, Myeongji-dong, Gangseo-gu,  
Busan 618-814, South Korea  
Tel: +85 51 580 8000  
Email: [info@prestigebio.com](mailto:info@prestigebio.com)

*a member of*  **CANCER MOONSHOT**

PBPID010424EN



IDC R&D CAMPUSES